Pfizer CEO Albert Bourla on Q3 earnings, patent expirations, obesity drug market
CNBC's Annika Kim Constantino and Albert Bourla, Pfizer CEO, join 'The Exchange' to discuss Pfizer's Q3 earnings, patent expirations, and more.
Fiscal Year: January - December
Pfizer Inc. (PFE), listed on the NYSE, has a market capitalization of $170.99B. As of Nov 04, 2026, the stock is trading at $30.00 per share@else an unavailable price , offering investors a clear view of its current market value. Pfizer Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 42.75, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Pfizer Inc. also offers a dividend yield of 5.73%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Pfizer Inc. (PFE) has a DCF fair value that is only shown to premium members. To see it, please Login or Upgrade for access.
The proprietary SS Score for Pfizer Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Pfizer Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Pfizer Inc. is 15.57, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Pfizer Inc. (PFE) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Pfizer Inc. (PFE) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Pfizer Inc. (PFE) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Pfizer Inc.. To access the full SS Score, consider upgrading your subscription.
Pfizer Inc. is a significant player in the industry sector, with a market capitalization of $170.99B and a competitive P/E ratio of 42.75. Investors should compare these metrics with industry peers to gauge whether Pfizer Inc. is outperforming or underperforming within its sector.
CNBC's Annika Kim Constantino and Albert Bourla, Pfizer CEO, join 'The Exchange' to discuss Pfizer's Q3 earnings, patent expirations, and more.
The major averages were mixed near noon, with the Dow fractionally lower but the S&P 500 and Nasdaq higher, as investors digest the latest spate of corporate earnings reports. Apple…
Pfizer ($PFE) and AstraZeneca ($AZN) are two pharmaceutical companies that offer dividends. Both offer dividend yields above the broader market, but Pfizer offers quarterly dividends, while AstraZenec...
Pfizer shares ($PFE) traded flat in Tuesday’s pre-market session even after the U.S. pharma giant beat Q3 earnings expectations and raised its 2026 sales forecast. The company now expects full-year…
Pfizer boosted its guidance for the year, citing momentum in newly-launched and acquired products that helped offset declining sales for its Covid-19 vaccine and treatments.
Pfizer boosts full-year guidance on the back of its latest quarter, citing growth in non-Covid offerings and acquired products.
Pfizer reported third-quarter results that topped estimates and hiked its full-year outlook, citing its "strong year-to-date performance" and ongoing cost cuts. Pfizer also announced that Cecile Gueg...
Reports Q3 revenue $16.6B, consensus $15.88B. Dr. Albert Bourla, Chairman and CEO of Pfizer (PFE): “Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing...
FY26 consensus $2.96. Raises FY26 revenue view to $62B-$64B from $60.5B-$62.5B, consensus $62.23B.
Pfizer raised its annual forecasts on Tuesday as strong demand for its cancer drugs and blockbuster blood thinner Eliquis helped the drugmaker post better-than-expected third-quarter results.
Pfizer (PFE) announced that its Board of Directors has unanimously appointed Cecile Guegan as CFO and Executive Vice President, effective November 1, 2026. Cecile has served as interim CFO since…
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS. EXE...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effectiv...
U.S. pharma giant Pfizer ($PFE) is set to release its third-quarter 2026 earnings tomorrow, November 3, before the market opens. Despite pressure on its COVID-19 business, Pfizer’s shares are up…
Ford, Pfizer and Verizon are among 11 stocks that passed a screen of the S&P 500 for high dividend yields that are expected to be well covered by the companies' free cash flow.
SAN FRANCISCO--(BUSINESS WIRE)--Edison Scientific announces agreement with Pfizer to accelerate research and development.
ManpowerGroup (MAN) announced the election of Lidia Fonseca, former Executive Vice President and Chief Digital and Technology Officer at Pfizer (PFE), to its Board of Directors, effective November 1. ...
Pfizer (PFE) announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO as monotherapy in adults with relapsed or refractory multiple myeloma who received at least one prior li...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or ref...
Pfizer (PFE) announced that the U.S. Food and Drug Administration has expanded approval of TALZENNA in combination with XTANDI to the treatment of men with metastatic androgen pathway modulation-naive...
Projected from reported cash flow (SEC filings). The starting point is the latest yearly revenue times the median free cash flow margin of the last five years. Years 1 to 5 grow at the revenue growth rate of the last five years (between -5% and 15%), and years 6 to 10 slow down to the 2.5% perpetual growth rate. These are Studying Stocks' own estimates, not analyst forecasts, and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | Source |
|---|---|---|---|
| 2026 | 10.49B | 8.48% | Projected |
| 2027 | 11.38B | 8.48% | Projected |
| 2028 | 12.35B | 8.48% | Projected |
| 2029 | 13.40B | 8.48% | Projected |
| 2030 | 14.53B | 8.48% | Projected |
| 2031 | 15.59B | 7.29% | Projected |
| 2032 | 16.54B | 6.09% | Projected |
| 2033 | 17.35B | 4.89% | Projected |
| 2034 | 17.99B | 3.70% | Projected |
| 2035 | 18.44B | 2.50% | Projected |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 9.84B | 1.00 | 9.84B |
| 2025A | 9.08B | 1.00 | 9.08B |
| 2026E | 10.49B | 1.07 | Login |
| 2027E | 11.38B | 1.15 | Login |
| 2028E | 12.35B | 1.24 | Login |
| 2029E | 13.40B | 1.33 | Login |
| 2030E | 14.53B | 1.43 | Login |
| 2031E | 15.59B | 1.54 | Login |
| 2032E | 16.54B | 1.65 | Login |
| 2033E | 17.35B | 1.78 | Login |
| 2034E | 17.99B | 1.91 | Login |
| 2035E | 18.44B | 2.05 | Login |
| Terminal | 2.05 | Login |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.